Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study.

Authors:
David M Kendall
David M Kendall
International Diabetes Center and University of Minnesota
United States
Cindy J Rubin
Cindy J Rubin
Pharmaceutical Research Institute
United States
Pharis Mohideen
Pharis Mohideen
Scripps Clinic
United States
Jean-Marie Ledeine
Jean-Marie Ledeine
Ben-Gurion University
Israel
Dr Paul Norwood, MD
Dr Paul Norwood, MD
University of California at San Francisco
Associate Clinical Professor of Medicine at UC San Francisco
Diabetes, cholesterol, hypertension,
Fresno, CA | United States

Diabetes Care 2006 May;29(5):1016-23

International Diabetes Center and the University of Minnesota, Minneapolis, Minnesota, USA.

Objective: We sought to evaluate the effects of muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor (PPAR) activator within the new glitazar class, on hyperglycemia and lipid abnormalities.

Research Design And Methods: A double-blind, randomized, controlled trial was performed in 1,159 patients with type 2 diabetes inadequately controlled with metformin. Patients received once-daily doses of either 5 mg muraglitazar or 30 mg pioglitazone for a total of 24 weeks in addition to open-label metformin. Patients were continued in a double-blind fashion for an additional 26 weeks.

Results: Analyses were conducted at week 24 for HbA1c (A1C) and at week 12 for lipid parameters. Mean A1C at baseline was 8.12 and 8.13% in muraglitazar and pioglitazone groups, respectively. At week 24, muraglitazar reduced mean A1C to 6.98% (-1.14% from baseline), and pioglitazone reduced mean A1C to 7.28% (-0.85% from baseline; P < 0.0001, muraglitazar vs. pioglitazone). At week 12, muraglitazar and pioglitazone reduced mean plasma triglyceride (-28 vs. -14%), apolipoprotein B (-12 vs. -6%), and non-HDL cholesterol (-6 vs. -1%) and increased HDL cholesterol (19 vs. 14%), respectively (P < 0.0001 vs. pioglitazone for all comparisons). At week 24, weight gain (1.4 and 0.6 kg, respectively) and edema (9.2 and 7.2%, respectively) were observed in the muraglitazar and pioglitazone groups; at week 50, weight gain and edema were 2.5 and 1.5 kg, respectively, and 11.8 and 8.9%, respectively. At week 50, heart failure was reported in seven patients (five with muraglitazar and two with pioglitazone), and seven deaths occurred: three from sudden death, two from cerebrovascular accident, and one from pancreatic cancer in the muraglitazar group and one from perforated duodenal ulcer in the pioglitazone group.

Conclusions: We found that 5 mg muraglitazar resulted in greater improvements in A1C and lipid parameters than a submaximal dose of 30 mg pioglitazone when added to metformin. Weight gain and edema were more common when muraglitazar was compared with a submaximal dose of pioglitazone.

Download full-text PDF

Source
http://dx.doi.org/10.2337/diacare.2951016DOI Listing
May 2006
27 Reads
23 Citations
8.420 Impact Factor

Publication Analysis

Top Keywords

muraglitazar pioglitazone
24
gain edema
12
weight gain
12
muraglitazar
12
pioglitazone
11
patients type
8
pioglitazone groups
8
proliferator-activated receptor
8
week muraglitazar
8
groups week
8
reduced a1c
8
pioglitazone reduced
8
double-blind randomized
8
week weight
8
metformin patients
8
controlled metformin
8
peroxisome proliferator-activated
8
inadequately controlled
8
diabetes inadequately
8
type diabetes
8

Similar Publications